Association between 894G>T polymorphism of nitric oxide synthase 3 (NOS3) gene and genetic susceptibility to prostate cancer: A Meta-analysis
10.3781/j.issn.1000-7431.2014.02.006
- Author:
Guang-Lei QIAO
1
Author Information
1. Department of Medical Oncology
- Publication Type:Journal Article
- Keywords:
894G>T;
Disease susceptibility;
Meta-analysis;
Nitric oxide synthase type III;
Polymorphism, single nucleotide;
Prostate neoplasms
- From:
Tumor
2014;34(2):135-140
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the association between the 894G>T polymorphism of nitric oxide synthase 3 (NOS3) gene and the susceptibility to prostate cancer. Methods: A computer-based online search was performed by using Cochrane Library, PubMed, EMBase, CNKI (China National Knowledge Infrasrtucture), Wanfang database and VIP database. The case-control studies were selected according to defined inclusion and exclusion criteria. After quality evaluation and data abstraction, a Meta-analysis was performed by using STATA 12.0 software. Odds ratio (OR) of the association between NOS3 894G>T and prostate cancer susceptibility was pooled. Then the subgroup analysis, sensitivity analysis and publication bias test were performed. Results: A total of 5 case-control studies were eligible for this analysis, including 3 078 cases and 3 677 healthy controls. Meta-analysis showed that NOS3 894G>T polymorphism didn't increase the risk of prostate cancer [TT vs GG, OR = 0.95, 95% confidence interval (CI): 0.80-1.14; TT vs GT, OR = 0.88, 95% CI: 0.73-1.05; TT+GT vs GG, OR = 1.07, 95% CI: 0.97-1.18; TT vs GG+GT, OR = 0.92, 95% CI: 0.77-1.09]. In the subgroup analysis of ethnicity, NOS3 894G>T polymorphism didn't increase the risk of prostate cancer in Europeans (TT vs GG, OR = 0.87, 95% CI: 0.73-1.04; TT vs GT, OR = 0.85, 95% CI: 0.71-1.02; TT+GT vs GG, OR = 1.00, 95% CI: 0.90-1.11; TT vs GG+GT, OR = 0.86, 95% CI: 0.72-1.02). Conclusion: NOS3 894G>T polymorphism is not associated with the prostate cancer susceptibility as well as in Europeans. Copyright © 2014 by TUMOR.
